| Description | This product is a human monoclonal antibody that reacts with TNFSF13B. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | FuncS; IF; Neut; ELISA; FC; IP; IHC |
| Application Notes | The antibody is recommended for detection of TNFSF13B by FuncS, IF, Neut, ELISA, FC, IP, IHC assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | TNFSF13B |
| Alternative Name | Tabalumab; 1143503-67-6; LY2127399; LY 2127399; TNFSF13B; tumor necrosis factor (ligand) superfamily, member 13b; TNFSF20; tumor necrosis factor ligand superfamily member 13B; BAFF; BLYS; CD257; TALL 1; TALL1; THANK; delta BAFF; Delta4 BAFF; B-lymphocyte stimulator; B-cel |
| Gene ID | 10673 |
| UniProt | Q9Y275 |
| Research Area | Immunology |
Figure 1 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in Western Blot.
Western blot analysis of V3S-0622-YC5689 was performed by loading recombinant human TNFSF13B with his-tag.
V3S-0622-YC5689 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-goat anti-human IgG
Lane 1: Reduced antigen (0.1 μg)
Lane 2: Reduced antigen (0.3 μg)
Lane 3: Reduced antigen (0.6 μg)
Figure 1 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in Western Blot.
Figure 2 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in ELISA.
ELISA analysis of V3S-0622-YC5689 was performed by coating with recombinant human TNFSF13B with his-tag.
The secondary antibody: HRP-goat anti-human IgG
Figure 2 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in ELISA.
Figure 3 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in Dot Blot.
Dot blot analysis of V3S-0622-YC5689 was performed by coating with recombinant human TNFSF13B with his-tag.
The secondary antibody: HRP-goat anti-human IgG
Figure 3 Anti-TNFSF13B Recombinant Antibody (V3S-0622-YC5689) in Dot Blot.
